A flurry of mergers in the healthcare sector appears poised to continue, as Bausch & Lomb is said to be ready to sell itself to Valeant Pharmaceuticals of Canada for about $9 billion. A deal could be announced as soon as Tuesday, people briefed on the matter said, though they said that talks were...
FULL STORY »